Table 1.
Clinical characteristics of patients with COVID-19 and patients of our ILD cohort.
| All hospitalized with COVID-19 in CHU Liège n = 687 |
ILD (n = 400) |
||||||
|---|---|---|---|---|---|---|---|
| Case 1 |
Case 2 |
Case 3 |
Case 4 |
Suggestive |
|||
| n (%) | SSc-ILD | Sarcoidosis | Chronic HP | Lipidic Pneumopathy | n = 33 | ||
| Gender, M (%) | 315 (53%) | F | M | M | F | 20 (61%) | |
| Age, Year | 58 ± 20 | 45 | 37 | 79 | 74 | 60 ± 14 | |
| Symptoms | Cough, N (%) | 268 (84%) | Yes | Yes | Yes | Yes | 22 (67%) |
| Dyspnea | 162 (51%) | – | Yes | Yes | Yes | 19 (58%) | |
| Chest pain | 105 (33%) | – | – | – | – | – | |
| Rhinorrhea | 167 (52%) | Yes | – | – | Yes | 14 (42%) | |
| Diarrhea | 99 (31%) | – | – | – | – | 5 (15%) | |
| Hyperthermia | 216 (68%) | Yes | Yes | Yes | Yes | 16 (48%) | |
| Asthenia | 201 (63%) | – | Yes | Yes | Yes | 17 (51%) | |
| Cephalalgia | 202 (64%) | – | Yes | Yes | – | 9 (27%) | |
| Hospitalization | 406 (59%) | 8 days | 5 days | >7 days | >7 days | 5 (15%) | |
| ICU | 55 (8%) | – | – | – | 6 days | ||
| Treatment | ECI, Azathioprine CS 10 mg/d |
– | CS 5 mg/d | ICS high dose | CS 14 (42%) IS 10 (30%) |
||
The data for symptoms are available for only 318 COVID-19 patients.
ECI: enzyme conversion inhibitor; CS: corticosteroids (Prednisolone); ICS: inhaled corticosteroids; IS: immunosuppressors (Azathioprine, Mycophenolate Mofetil, Ledertrexate); ICU: intensive care unit; ILD: interstitial lung disease; SSc-ILD: systemic sclerosis-associated interstitial lung disease.
All the ILD patients were contacted by phone (at least 2 attempts). In total, 77% of them responded. Patients were suspected to have COVID-19 when they experienced at least one of the COVID-19-specific symptoms of acute onset.